StockData
INABNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

IN8BIO, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.09−0.02 (-1.80%)

Close on Oct 19, 2026

Market cap
$21.22M
P/E (TTM)
–
Dividend yield
–

IN8BIO, INC. revenue by segment

No segment breakdown reported

In8bio does not break out revenue by segment, region or product in the tagged data of its filings for this period type.